Introduction {#sec1-1}
============

Cancer is one of the leading causes of morbidity and mortality worldwide, with approximately 14 million new cases in 2012. Approximately 2.2 million (15.4%) of cases are attributed to carcinogenic infections, mainly human papillomavirus (HPV) (Plummer et al., 2016). HPV is associated with 99.7% of cervical cancer cases (Walboomers et al., 1999) and is implicated in the pathogenesis of other ano-genital malignancies (Crawford et al., 2011).

The carcinogenic effect of HPV depends on integration of the virus into the host-cell DNA and expression of the oncoproteins E6 and E7, which antagonize the functions of the tumor-suppressor proteins p53 and pRb, respectively (Damin et al., 2013). Twelve HPV types are classified as "high risk" (HPV: 16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58, and 59), and eight are probably or possibly oncogenic (HPV: 26, 53, 66, 67, 68, 70, 73, and 82) (Almeida et al., 2017).

HPV types 16 and 18, classified as high-risk viruses for cervical cancer, are currently considered as human carcinogens by the International Agency for Research on Cancer (Humans, 1995). However, the cancer-causing effects of HPV are not limited to the cervix; an estimated 50% of penile, 88% of anal, 43% of vulvar, 70% of vaginal, and 13--56% of oropharyngeal cancers are attributable to HPV, primarily HPV 16 and typically followed by HPV 18 (De Vuyst et al., 2009; WHO, 2013). Of these, anal cancer is the most strongly associated with HPV, yet much less is known of the natural history of anal compared to cervical infection (Crawford et al., 2011). Other studies have also shown the association of HPV and non-cervical cancers (Ang et al., 2011; De Vuyst et al., 2009; O'Sullivan et al., 2016; Zandberg et al., 2013).

HPV has a well-recognized etiological role in cervical and non-cervical cancers (Ang et al., 2011; Hu et al., 2015; Zandberg et al., 2013), however, the lack of consistent results from data on non-cervical cancer creates limitations to the planning of surveillance and control measures. The understanding of the prevalence of HPV in non-cervical cancers and the knowledge of the distribution of the viral subtypes are important epidemiological information that can help the development of local or regional public policies. We performed a systematic review and meta-analysis of studies carried out in Brazil on HPV infection and the development of prostate, anal, colorectal, penile and vulvar cancers, and in parallel, aimed to determine the prevalence and main HPV genotypes involved in cancers of the selected anatomical sites.

Materials and Methods {#sec1-2}
=====================

This review was conducted in accordance with the recommendations outlined in the Preferred Reporting Items for Systematic Reviews and Meta-analyses (PRISMA) Statement (Moher et al., 2015).

Search strategy {#sec2-1}
---------------

We searched the literature articles published from January 1, 2006 and December 31, 2016 that evaluated the prevalence and possible association between non-cervical genital cancer and HPV in Brazil. This stage was computed by five independent investigators (CMS, LDP, VLB, JP, and MT \["Group 1"\]) that carried out the specific research to define the maximum possible Medical Subject Heading (MeSH) terms. Discrepancies or disagreements were resolved by consensus with support and validation of a specialist (JJVT). In the first phase, the researchers from Group 1 conducted the search in PubMed, Web of Knowledge databases, and Scholar Google system to find original articles, using as search criterion a combination of the following keywords organized in three blocks: Block 1: "penile neoplasms", "Vulvar neoplasms", "Vaginal neoplasms", "Rectal Neoplasms", "Prostatic Neoplasms", "Adenocarcinoma", "Anus Neoplasms", "Carcinoma, Adenosquamous", "Carcinoma, Squamous Cell", "Genotype", "Papillomaviridae", "Papillomavirus infections", Block 2: "Clinical Laboratory Techniques", "Genotyping techniques", "Human Papillomavirus DNA Tests", "In Situ Hybridization", "Molecular biology", " Multiplex Polymerase Chain Reaction", "Polymerase Chain Reaction", "Polymorphism, Restriction Fragment Length", "Random Amplified Polymorphic DNA Technique", "Real-Time Polymerase Chain Reaction", "Reverse Transcriptase Polymerase Chain Reaction", and Block 3: "Brazil".

The PubMed search used a combination of Medical Subject Heading Terms; search on Web of Knowledge was made by topic; and the freely accessible Scholar Google system was used to perform a search using the same MeSH terms in different combinations. The identified studies were compiled into a database, and citations were initially screened by title and abstract to assess the potential eligibility.

The strategy used to design this study is described in the flow diagram ([Figure 1](#F1){ref-type="fig"}). Abstracts were reviewed, and full-text articles of potentially relevant studies were examined independently by investigators in Group 1 and Group 2 (JJVT, CG, VS, FG and MELC) for the updated search against pre-specified selection criteria. Data were independently extracted by Group 1 and compared. If there was doubt about the suitability of the paper based on the abstract, the full text was reviewed. We also manually searched the references of selected articles for retrieval of publications not selected in the search. Any disagreements or discrepancies were resolved by consensus-based discussions. Cross-checking of bibliographies from other published reviews and from all retrieved articles was conducted to identify additional publications. The corresponding author was contacted whenever we had questions about the eligibility of the article or critical data were missing. Online searches were conducted between May 10, 2017 and August 31, 2017.

![Flow Diagram of Selected Studies for Systematic Review. In Total, 18 Studies Met the Inclusion Criteria](APJCP-19-2359-g001){#F1}

Inclusion and exclusion of studies {#sec2-2}
----------------------------------

We have included only the primary studies conducted in Brazil between 2006 and 2016 published in the medical literature that reported the prevalence of HPV in non-cervical genital cancers (prostate, penile, vulvar, colorectal, anal canal), as well as those reporting genotypes present in each case, detected by molecular biology techniques. Individuals were classified as having cancer by pathological analysis.

We excluded studies that evaluated the presence of HPV by cytological methods, systematic reviews and reviews, clinical trials, letters, comparative studies, those mainly with HIV positive or negative cases, case reports, studies that did not present analysis of the HPV genotypes, and duplicate publications. No restrictions on sex and age were applied.

Data extraction {#sec2-3}
---------------

For data extraction, researchers from Group 1 located articles in PDF format to check for the retention or otherwise of the publications in the study. The articles were randomized and distributed among Group 1 researchers for independent reading, followed by validation through consensus. The entries were checked by researchers from Group 2. This group also analyzed the content extracted from each article individually and included it in the tables, and any discrepancies in the results described in the tables were resolved by consensus. Whenever there was a doubt about the suitability of the paper based on the abstract, the full text was reviewed.

We extracted the following information from all eligible studies: study objectives, method used, period of sampling, age of patients, anatomical location of the cancers, number of patients who were part of the study, prevalence of HPV in the samples, prevalence of HPV genotypes (6, 11, 16, 18, 26, 28, 31, 33, 35, 39, 42, 45, 51, 52, 53, 54, 58, 62, 67, 68, 69, 70, 71, 73, 82 and 84), and prevalence of simple infections and coinfections among HPV genotypes.

For studies in which only the patient numbers were reported, prevalences were estimated in relation to the genotyped samples number. The total prevalence of each specific genotype in each study was estimated independent of the presence of single infection or coinfection. For the determination of the prevalence of simple infection/coinfection, where this was not described, it was estimated based on the approximate values reported in the articles. Ethical approval was not required for this study as it was based on data/information retrieved from published studies already available in the public domain.

Statistical analysis {#sec2-4}
--------------------

All the statistical analyses for the meta-analysis were developed in Stata 9.0® software (Stata Corporation, College Station, TX, USA), by means of the Metan Command, with statistical significance at p \< 0.05. The data extracted from the papers for the development of the forest plot are described in [Table 1](#T1){ref-type="table"}. The estimated effect measure grouped for the variability among the groups was determined by the odds ratio (OR), with a confidence interval of 95%. Fixed effects models and random effects models were initially tested. HPV prevalences at each anatomical site and prevalences of HPV genotypes were obtained from the studies to determine the consistency of the results. To estimate the pooled prevalence of total HPV and at each anatomical site, the pooled prevalence of each HPV genotype and the presence of simple infection and coinfection, the random effects method was used (DerSimonian and Nan Laird, 2015), with a 95% confidence interval.

###### 

Characteristics of Included Studies in Systematic Review

  Study                         Local (city/state) and sampling period (years)         Brief HPV related objectives of the study                                                                                                                                                                 Patients (n)                            Age group of CA pacients (years)         Diagnosis (Detection and genotyping)   HPV in CA patients n (%)   HPV16 in HPV/CA patiens (%)   Single HPV infection prevalence n (%)   Multiple HPV infection prevalence n (%)
  ----------------------------- ------------------------------------------------------ --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- --------------------------------------- ---------------------------------------- -------------------------------------- -------------------------- ----------------------------- --------------------------------------- -----------------------------------------
  Scheiner et al, 2008          Rio de Janeiro, RJ 1995-2000                           To assess the prevalence of HPV infection in penile carcer.                                                                                                                                               Total: 80 With CA: 80                   Mean age: 57.6 (36 - 86)                 PCR and RFLP                           58 (72.5)                  12 (52) Evaluated: 23         23 (100) Evaluated: 23                  0 (0)
  Afonso et al, 2012            Rio de Janeiro, RJ 2007-2010                           To determine HPV prevalence rates and main genotypes present in penile cancer.                                                                                                                            Total: 135 With CA: 135                 Mean age: 58.5 (21 - 87)                 PCR and RFLP                           82 (60.7)                  27 (29.7)                     NR                                      7 (9.2)
  Fonseca et al, 2013           Belém, PA 2001-2008                                    To evaluate the prevalence, distribution and association of HPV infection with worse prognosis in penile cancer and to determine predictive value metastasis.                                             Total: 82 With CA: 82                   Median age: 58 (22 - 91)                 PCR                                    50 (60.9)                  15 (30)                       NR                                      25 (50)
  Sousa et al, 2015             São Luiz, MA 2001- 2011                                To determine the prevalence of HPV-DNA in penile cancer and to correlate the virus presence to histopathological factors.                                                                                 Total: 76 With CA: 76                   Mean age: 60.7 (26 - 97)                 PCR                                    48 (63.1)                  10 (21.3)                     NR                                      25 (51.0)
  Termini et al, 2015           São Paulo, SP 1953 -- 2000                             To evaluate the association of SOD2 immunoexpression with HPV DNA presence in penile cancer.                                                                                                              Total: 125 With CA: 125                 \<50 (34.4%) 50--59(32.8%) ≥60 (32.8%)   PCR                                    26 (20.8)                  17 (65.4)                     NR                                      4 (15,4)
  Calmon et al, 2013            São José do Rio Preto and São Paulo, SP Belém, PA NR   To identify novel genes expressed in penile cancer HPV positive and evaluate a correlation between HPV positivity, the expression of the genes and the subtypes of penile cancer.                         Total: 47 With CA: 47                   Mean age: 63 (31 - 95)                   INNO-LiPA                              23 (48.9)                  19 (82.6)                     21 (91.3)                               2 (8.7)
  Busso Lopes et al,2014        Barretos e São Paulo -- SP 2000 -- 2010                To identify potential molecular markers in penile cancer and evaluate the viral role in penile tumors biology.                                                                                            Total: 46 With CA: 46                   NR                                       Linear Array                           16 (34.8)                  14 (87.5)                     13 (81,2)                               3 (18.7)
  Kuasne et al, 2015            São Paulo e Barretos, SP NR                            To identify molecular markers for penile cancer and to determine if HPV status influenced in gene expression levels and methylation patterns.                                                             Total: 87 Without CA: 43 With CA: 44    Mean age: 57.2 (24 - 92)                 Linear Array                           17 (38.6)                  15 (88,2)                     NR                                      NR
  Araujo-Neto et al, 2016       Teresina, PI 2011 -- 2013                              To examine the prevalence of HPV infections in prostate câncer                                                                                                                                            Total: 104 With CA: 104                 Mean age: 68 (45 - 90)                   Nested PCR                             0 (0)                      0 (0)                         0 (0)                                   0 (0)
  Silvestre et al, 2009         Belém, PA NR                                           To detect HPV DNA in samples of prostate cancer and in prostatic hyperplasia.                                                                                                                             Total: 71 Without CA: 6 With CA: 65     Mean age: With CA: 62                    Linear Array                           2 (3)                      2 (100)                       0 (0)                                   2 (100)
  Soares et al, 2011            Belém, PA 1998 - 2000                                  To identify HPV types in the carriers of anal canal cancer, relating them to the degree of cellular differentiation and staging of the lesion                                                             Total: 75 Without CA: 42 With CA: 33    Mean age: With CA: 48.5                  PCR and Dot blot                       20 (60.6)                  14 (70)                       19 (95)                                 1 (5)
  Picanç-Junior et al, 2015     Belém, PA 1999 -- 2003                                 To correlate the HPV presence with the staging and degree of cell differentiation among colorectal cancer the possibility of this relationship with prognostic factors.                                   Total: 144 Without CA: 65 With CA: 79   Mean age: 57,8 (25 - 85)                 PCR and Dot blot                       41/144 (45.6)              36 (100)                      36 (100)                                0 (0)
  Damin et al, 2007             Porto Alegre, RS 2004-2005                             To investigate the presence of HPV in colorectal cancer and the correlation of the viral infection with prognostic factors for the disease outcome.                                                       Total: 72 With CA: 72                   Mean age: 64.1 (39 - 75)                 Nested PCR                             60 (83.3)                  41 (68.3)                     41 (68.3)                               19 (31.7)
  Lavorato Rocha et al, 2013a   São Paulo, SP 1979 -- 2006                             To evaluate the prognostic relevance of CDKI in vulvar cancer and their relation with HPV infection.                                                                                                      Total: 139 With CA: 139                 Mean age: 69 (15 - 98)                   Linear Array                           43 (41) Evaluated: 105     18 (41.9)                     33/41 (76.6) Related: 41                8/41 (17) Related: 41
  Rodrigues et al,2013          São Paulo, SP 1979 -- 2006                             To evaluate the expression of E-cadherin, b-catenin, Snail, Slug, Twist and Vimentin in vulvar cancer and associated their expression with clinical data and the presence of HPV.                         Total: 87 With CA: 87 Total: 139        Mean age: 68.7 (46 - 90)                 Linear Array                           34 (39.1)                  17 (49.9)                     26 (76.6)                               8 (23.5)
  Lavorato Rocha et al, 2013b   São Paulo, SP 1979 -2006                               To determine the prognostic role of p14ARF in vulvar cancer its involvement in the p53 pathway, and in the context of HPV infection, and correlating these results with clinical and pathological data.   With CA:139                             Mean age: 69 (15- 98)                    Linear Array                           38 (32.8) Evaluated: 85    19 (49.9)                     28 (70.6)                               10 (26.3)
  Akagi et al, 2014             São Paulo, SP 1990 -- 2010                             To determine the prognostic value of ROCK1 gene and protein analysis in vulvar cancer, and correlated with clinicopathological characteristics.                                                           Total: 96 With CA: 96                   Mean age: 75 (30 -- 103)                 Linear Array                           46 (48)                    22 (48)                       NR                                      NR
  Maia et al,2012               São Paulo, SP 1979 - 2006                              To determine the prognostic importance of c-KIT by evaluation its protein and mRNA expression in vulvar cancer and correlating with clinicopathological features and HPV infection.                       Total: 103 With CA: 103                 Mean age: 69 (15 -- 98)                  Linear Array                           60 (58,2)                  26 (44.2)                     46 (77)                                 7 (11.6)

CA -- cancer, MA -- Maranhão, PA -- Pará, PI -- Piauí, RJ -- Rio de Janeiro, RS -- Rio Grande do Sul, SP -- São Paulo, NR -- Not related, CDKI - cyclin-dependent kinase inhibitors

Subgroup analysis {#sec2-5}
-----------------

The subgroups were analyzed according to the proportions between the presence and absence of HPV in the general prevalence of non-cervical genital cancers and at each anatomical site. The pooled total prevalence of HPV genotypes 6, 11, 16, 18, 31, 33, 35, 45 and 53, as well as the pooled prevalence of genotypes 6, 11, 16, 18 and 45 in penile cancer, 16, 18, 33, 35 and 53 in vulvar cancer, and 16 in colorectal cancer were determined.

Heterogeneity and publication bias {#sec2-6}
----------------------------------

The heterogeneity between the studies was analyzed according to Cochran's Q statistical test (p \< 0.10) as indicative of significance. The publication bias was verified using Begg's (Begg and Mazumdar, 1994) and Egger's (Egger et al., 1997) methods, as well as the funnel plots, with statistical significance at p \< 0.05. The inconsistency of the findings was performed by I2 statistic according to the classification: low (25%), moderate (50%), and high (75%) (Higgins et al., 2003).

Results {#sec1-3}
=======

The electronic search yielded 2,630 citations. Based on titles and abstracts, 886 publications were eliminated. After abstract review, 1,726 publications were further excluded. The remaining 18 studies were included in the analysis ([Figure 1](#F1){ref-type="fig"} and [Table 1](#T1){ref-type="table"}) (Afonso et al., 2012; Akagi et al., 2014; Araujo-Neto et al., 2016; Busso-Lopes et al., 2015; Calmon et al., 2013; Damin et al., 2007; Fonseca et al., 2013; Kuasne et al., 2015; Lavorato-Rocha et al., 2013a; Lavorato-Rocha et al., 2013b; Melo Maia et al., 2012; Picanço-Junior et al., 2014; Rodrigues et al., 2013; Scheiner et al., 2008; Silvestre et al., 2009; Soares et al., 2011; Sousa et al., 2015; Termini et al., 2015). The total number of individuals included in the study was 1,708, of which 1,552 had cancer. According to the geographical distribution of the studies, 72 individuals were from the Southern region (Damin et al., 2007), 994 from the Southeast region (Afonso et al., 2012; Akagi et al., 2014; Busso-Lopes et al., 2015; Kuasne et al., 2015; Lavorato-Rocha et al., 2013a; Lavorato-Rocha et al., 2013b; Rodrigues et al., 2013; Scheiner et al., 2008; Termini et al., 2015), 180 from the Northeast region (Araujo-Neto et al., 2016; Sousa et al., 2015) and 259 from the Northern region of Brazil (Fonseca et al., 2013; Picanço-Junior et al., 2014; Silvestre et al., 2009; Soares et al., 2011;). Only one study, with 47 individuals, comprised samples from the Southeast and Northeast regions (Calmon et al., 2013). According to publication years, 3/18 (16.67%) (Damin et al., 2007; Scheiner et al., 2008; Silvestre et al., 2009), 2/18 (11.11%) (Afonso et al., 2012; Soares et al., 2011), and 13/18 (72.22%) (Akagi et al., 2014; Araujo-Neto et al., 2016; Busso-Lopes et al., 2015; Calmon et al., 2013; Fonseca et al., 2013; Kuasne et al., 2015; Lavorato-Rocha et al., 2013a; Lavorato-Rocha et al., 2013b; Sousa et al., 2015; Termini et al., 2015; Rodrigues et al., 2013), of the studies were published in the periods 2006--2009, 2010--2012, and 2013--2016, respectively. The mean/median age of individuals was specified in 17/18 (94.44%) of the studies, ranging from 15 to 103 years. Sample sizes across the studies ranged from 33 to 139 and the sampling period ranged from 1 to 47 years. This information was not presented in 3/18 (16.66%) of the studies.

Of the total number of studies selected in this review, 8/16 (50%) corresponded to the research performed on penile cancer (Afonso et al., 2012; Busso-Lopes et al., 2015; Calmon et al., 2013; Fonseca et al., 2013; Kuasne et al., 2015; Scheiner et al., 2008; Sousa et al., 2015; Termini et al., 2015), 2/18 (11.11%) in prostate cancer (Araujo-Neto et al., 2016; Silvestre et al., 2009), 1/18 (5.55%) in anal canal cancer (Soares et al., 2011), 2/18 (11.11%) colorectal cancer (Damin et al., 2007; Picanço-Junior et al., 2014) and 5/18 (27.28%) in vulvar cancer (Akagi et al., 2014; Lavorato-Rocha et al., 2013a; Lavorato-Rocha et al., 2013b; Rodrigues et al., 2013; Melo Maia et al., 2012). For HPV diagnosis (detection and genotyping), 3/18 (16.67%) of the studies used only polymerase chain reaction (PCR) (Fonseca et al., 2013; Sousa et al., 2015; Termini et al., 2015), 2/18 (11.11%) used PCR and Restriction Fragment Length Polymorphism (RFLP) (Afonso et al., 2012; Scheiner et al., 2008), 2/18 (11.11%) PCR and Dot Blot Hybridization (Dot blot) (Picanço-Junior et al., 2014; Soares et al., 2011), 2/18 (11.11%) Nested PCR (Araujo-Neto et al., 2016; Damin et al., 2007), 8/18 (44.44%) Linear Array HPV Genotyping (Linear Array) (Akagi et al., 2014; Busso-Lopes et al., 2015; Kuasne et al., 2015; Lavorato-Rocha et al., 2013a; Lavorato-Rocha et al., 2013b; Melo Maia et al., 2012; Rodrigues et al., 2013; Silvestre et al., 2009) and 1/18 (5.55%) INNO-LiPA® HPV Genotyping Extra text (INNO-LiPA) (Calmon et al., 2013). [Table 1](#T1){ref-type="table"} summarizes the study retrieval steps. In 14/18 (77.8%) of the studies, only cancer samples were used for HPV screening; however, in 4/18 (22.2%) of the studies, the prevalence of HPV in normal tissue was also sought.

The prevalence of HPV ranged from 0 to 83.3%, with an overall prevalence of 43% (95% CI: 36--51%; p \< 0.001) ([Figure 2](#F2){ref-type="fig"}), with great variation according to the study sites. For penile cancer, the prevalence of HPV ranged from 20.8 to 72.5%, yielding a pooled prevalence of 42% (95% CI: 32-55%, p \< 0.001) ([Figure 3A](#F3){ref-type="fig"}). For colorectal cancer, two studies showed a prevalence of HPV of 45.6 and 83.3% and a pooled prevalence of 67% (95% CI: 64-70%, p \< 0.001) ([Figure 3B](#F3){ref-type="fig"}). For vulvar cancer, HPV ranged from 39.1 to 58.2%, yielding a pooled prevalence of 43% (95% CI: 34-55%, p \< 0.001) ([Figure 3C](#F3){ref-type="fig"}).

![HPV Pooled Prevalence in Non-cervical Genital Cancer Patients](APJCP-19-2359-g002){#F2}

![HPV Pooled Prevalence in Penile Cancer Patients (A), Colorectal Cancer Patients (B) and Vulvar Cancer Patients (C)](APJCP-19-2359-g003){#F3}

Genotype 16 was the only one found and reported in all cancers presented in this review. This genotype was also the most prevalent (54%, 95% CI: 44-66%, p \< 0.001), followed by HPV 33 (21%, 95% CI 17-28%, p \< 0.001), HPV 6 (15%, 95% CI 8-26%, p \< 0.001) and HPV 11 (13%, 95% CI 5-32%, p \< 0.001). In the samples of penile cancer, the most prevalent genotypes were 16 (51%, 95% CI: 35-73%, p \< 0.001) and 6 (17%, 95% CI: 8-33%, p \< 0.001). In vulvar cancer, a higher prevalence of genotypes 16 (46%, 95% CI: 43-49%, p = 0.293) and 33 (26%, 95% CI: 23-29%, p = 0.256) were found. For colorectal cancer, it was only possible to determine the prevalence of genotype 16 (78%, 95% CI 73-83%, p \< 0.001). The pooled prevalence of prostate and anal canal cancers were not determined because the prevalence of HPV in prostate cancer reported in one of the articles was equal to 0 and only one article was identified for cancer of the anal canal ([Table 2](#T2){ref-type="table"}, [Table 3](#T3){ref-type="table"} and Supplementary file 1).

###### 

Pooled Prevalence of Human Papillomavirus Genotypes in Cancer Patients

  Total                      Number of studies   Number of cases   Pooled HPV prevalence   95% CI    p         I2 (%)
  -------------------------- ------------------- ----------------- ----------------------- --------- --------- --------
  Genotypes HPV                                                                                                
   16                        17                  324               54                      44 - 66   \<0.001   96.5
   33                        9                   62                21                      17 - 28   \<0.001   75.5
   6                         6                   40                15                      8-26      \<0.001   93.0
   11                        7                   56                13                      5-32      \<0.001   97.3
   18                        12                  73                12                      7-22      \<0.001   95.5
   53                        6                   22                10                      6-16      0.009     67.2
   35                        7                   13                7                       4-11      0.281     19.6
   31                        7                   11                4                       3-7       0.942     00.0
   45                        7                   27                4                       1-15      \<0.001   79.6
  Penile HPV genotypes                                                                                         
   16                        8                   129               51                      35 - 73   \<0.001   96.7
   6                         4                   32                17                      8-33      \<0.001   94.6
   11                        5                   48                15                      5-41      \<0.001   97.1
   18                        6                   19                8                       4-18      \<0.001   86.2
   45                        4                   24                6                       1-29      0.002     80.0
  Vulvar HPV genotypes                                                                                         
   16                        5                   102               46                      43-49     0.293     19.1
   33                        5                   57                26                      23-29     0.256     24.8
   18                        4                   16                13                      10-17     0.252     26.7
   53                        3                   11                10                      7-14      0.662     00.0
   35                        3                   9                 9                       5-14      0.267     24.3
  Colorectal HPV genotypes                                                                                     
   16                        2                   77                78                      73 - 83   \<0.001   96.7

HPV, Human papillomavirus; OR, odds ratio; CI, confidence interval

###### 

HPV Genotypes Prevalence Related in Cancer Patients of Included Studies in Systematic Review

  Genotype prevalence (%)                                                                                                                                                                            
  ------------------------- ------- ------ ------ ------ ------ ----- ----- ----- ------ ------ ----- ------ ----- ------ ---- ---- ------ ----- ---- ----- ----- ---- ----- ----- ----- ----- ----- -----
  Anatomic site             Study   6      11     16     18     26    28    31    33     35     39    40     42    45     51   52   53     54    58   62    67    68   69    70    71    73    82    84
                                                  \*     \*           \*    \*    \*     \*     \*                 \*     \*   \*   \*           \*               \*                     \*    \*    
                            1       17.4   \-     52.1   4.3    \-    8.7   4.3   4.3    \-     \-    \-     \-    4.3    \-   \-   \-     \-    \-   \-    \-    \-   \-    \-    4.3   \-    \-    \-
                            2       9.9    2.4    29.7   5.5    1.2   2.4   4.9   1.2    1.2    \-    \-     \-    23.1   \-   \-   1.2    \-    \-   2.4   \-    \-   \-    1.2   2.4   1.2   \-    \-
                            3       32     64     30     2      \-    \-    \-    4      \-     \-    \-     \-    2      2    2    18     \-    2    \-    \-    2    \-    \-    \-    \-    \-    \-
                            4       \-     12.8   21.3   8.5    \-    \-    \-    \-     \-     \-    \-     \-    2.1    \-   \-   \-     \-    \-   \-    \-    \-   4.2   \-    \-    \-    \-    \-
                            5       11.5   11.5   65.4   26.9   \-    \-    \-    \-     3.8    3.8   \-     \-    \-     \-   \-   \-     \-    \-   \-    \-    \-   \-    \-    \-    \-    \-    \-
                            6       \-     21.7   82.6   \-     \-    \-    \-    \-     4.3    \-    \-     \-    \-     \-   \-   \-     \-    \-   \-    \-    \-   \-    \-    \-    \-    \-    \-
                            7       \-     \-     87.5   \-     \-    \-    \-    \-     \-     \-    \-     \-    \-     \-   \-   6.2    \-    \-   6.2   \-    \-   \-    \-    \-    \-    \-    \-
  Penis                     8       \-     \-     88,2   □      \-    \-    □     □      \-     \-    12.5   \-    \-     \-   \-   \-     \-    \-   \-    \-    \-   \-    \-    \-    \-    \-    \-
  Prostate                  9       \-     \-     \-     \-     \-    \-    \-    \-     \-     \-    \-     \-    \-     \-   \-   \-     \-    \-   \-    \-    \-   \-    \-    \-    \-    \-    \-
                            10      \-     \-     100    \-     \-    \-    \-    \-     \-     \-    \-     \-    \-     \-   \-   \-     \-    \-   \-    \-    \-   \-    \-    \-    \-    \-    100
  Anal canal                11      5      5      70     25     \-    \-    5     5      5      \-    \-     \-    \-     \-   \-   \-     \-    \-   \-    \-    \-   \-    \-    \-    \-    \-    \-
  Colorectal                12      \-     \-     100    \-     \-    \-    \-    \-     \-     \-    \-     \-    \-     \-   \-   \-     \-    \-   \-    \-    \-   \-    \-    \-    \-    \-    \-
                            13      11.7   11.7   68.3   50     \-    \-    1.7   \-     \-     \-    \-     \-    \-     \-   \-   \-     \-    \-   \-    \-    \-   \-    \-    \-    \-    \-    \-
                            14      \-     \-     42     7      \-    \-    \-    25     6      \-    \-     4     2      \-   \-   9      4     \-   \-    5     \-   2     \-    5     \-    2     2
                            15      \-     \-     50     11.7   \-    \-    \-    29.4   11.7   \-    \-     2.9   2,9    \-   \-   11.8   2.9   \-   \-    \-    \-   \-    \-    5.9   \-    2.9   2.9
                            16      \-     \-     49.9   13.1   \-    \-    2.6   26.2   7.8    \-    \-     5.2   2.6    \-   \-   7.9    5.2   \-   \-    5.3   \-   2.6   \-    2.6   \-    2.6   2.6
                            17      \-     \-     48     15     \-    \-    \-    24     \-     \-    \-     \-    \-     \-   \-   \-     \-    \-   \-    \-    \-   \-    \-    \-    \-    \-    \-
  Vulva                     18      \-     \-     44.2   \-     \-    \-    \-    27.9   \-     \-    \-     \-    \-     \-   \-   \-     \-    \-   \-    \-    \-   \-    \-    \-    \-    \-    \-

□Presence reported, but with prevalence not described. Asterisks indicate high-risk HPV genotypes. Studies, 1 - Scheiner et al., 2008; 2 - Afonso et al., 2012; 3 - Fonseca et al., 2013; 4 - Sousa et al., 2015; 5 - Termini et al., 2015; 6 - Calmon et al., 2013; 7 - Busso Lopes et al., 2014; 8 - Kuasne et al., 2015; 9 - Araujo-Neto et al., 2016; ; 10 - Silvestre et al., 2009; 11 - Soares et al., 2011; 12 - Picanço-Junior et al., 2015; 13 - Damin et al., 2007; 14 - Lavorato-Rocha et al., 2013a; 15 - Rodrigues et al., 2013; 16 - Lavorato Rocha et al., 2013b; 17 - Akagi et al., 2014; 18 - Maia et al., 2012

Infections by one and multiple HPV genotypes were reported in 12/18 (66.67%) (Araujo-Neto et al., 2016; Busso-Lopes et al., 2015; Calmon et al., 2013; Damin et al., 2007; Lavorato-Rocha et al., 2013a; Lavorato-Rocha et al., 2013b; Melo Maia et al., 2012; Picanço-Junior et al., 2014; Rodrigues et al., 2013; Scheiner et al., 2008; Silvestre et al., 2009; Soares et al., 2011) and in 16/18 (88.89%) (Afonso et al., Araujo-Neto et al., 2016; 2012; Busso-Lopes et al., 2015; Calmon et al., 2013; Damin et al., 2007; Fonseca et al., 2013; Lavorato-Rocha et al., 2013a; Lavorato-Rocha et al., 2013b; Melo Maia et al., 2012; Picanço-Junior et al., 2014; Rodrigues et al., 2013; Scheiner et al., 2008; Silvestre et al., 2009; Sousa et al., 2015; Soares et al., 2011; Termini et al., 2015), of the studies, respectively. The prevalence of infection by a single HPV genotype was 82% (95% CI: 75-90%, p \< 0.001), the most common being genotype 16 (60%). Infection by multiple HPV genotypes was described in 72.2% of the studies in this review, with a mean prevalence of 22% (95% CI: 15-30%, p \< 0.001), with coinfection by genotypes 16 and 18 being 34% ([Table 4](#T4){ref-type="table"} and Supplementary file 2).

###### 

Prevalence of HPV Genotypes in Multiple Infections in Genital Non Cervical Cancer Patients

  HPV multiple infections   Patients n (%)   Anatomic site   Studies
  ------------------------- ---------------- --------------- -------------------------------
  16\*/11                   1 (1.7)          Penis           Calmon et al., 2013
  16\*/18\*                 12 (20.3)        Colorectal      Damin et al., 2007
                                             Vulva           Lavorato-Rocha et al., 2013b
  16\*/31\*                 2 (3.4)          Colorectal      Damin et al., 2007
                                             Vulva           Lavorato-Rocha et al., 2013b
  16\*/ 33\*                6 (10.2)         Vulva           Lavorato-Rocha et al., 2013a;
                                                             Lavorato-Rocha et al., 2013b;
                                                             Rodrigues et al., 2013
  16\*/40                   1 (1.7)          Penis           Busso Lopes et al., 2014
  16\*/ 45\*                1 (1.7)          Penis           Afonso et al., 2012
  16\*/62                   1 (1.7)          Penis           Busso Lopes et al., 2014
  16\*/84                   2 (3.4)          Prostate        Silvestre et al., 2009
  16\*/6/11                 5 (8.5)          Penis           Termini et al., 2015;
                                             Colorectal      Damin et al., 2007
  16\*/33\*/35\*            2 (3.4)          Vulva           Lavorato-Rocha et al., 2013a;
                                                             Lavorato-Rocha et al., 2013b;
                                                             Rodrigues et al., 2013
  16\*/18\*/33\*            3 (5.1)          Vulva           Lavorato-Rocha et al., 2013b;
                                                             Lavorato-Rocha et al., 2013a;
                                                             Rodrigues et al., 2013
  16\*/18\*/39\*            1 (1.7)          Penis           Termini et al., 2015
  16\*/33\*/ 84             3 (5.1)          Vulva           Lavorato-Rocha et al., 2013a;
                                                             Lavorato-Rocha et al., 2013b;
                                                             Rodrigues et al.,2013
  18\*/40                   1 (1.7)          Penis           Busso Lopes et al., 2014
  18\*/33\*/35\*            2 (3.4)          Vulva           Lavorato-Rocha et al., 2013a
  6/11                      2 (3.4)          Penis           Afonso et al., 2012;
                                                             Termini et al., 2015
  6/11/18\*                 3 (5.1)          Colorectal      Damin et al., 2007
  6/11/45\*                 1 (1.7)          Penis           Afonso et al., 2012
  6/31\*                    1 (1.7)          Penis           Afonso et al., 2012
  6/45\*                    1 (1.7)          Penis           Afonso et al., 2012
  11/35\*                   1 (1.7)          Penis           Calmon et al., 2013
  31\*/33\*/82\*            3 (5.1)          Vulva           Lavorato-Rocha et al., 2013a;
                                                             Lavorato-Rocha et al., 2013b;
                                                             Rodrigues et al., 2013
  42/54                     3 (5.1)          Vulva           Lavorato-Rocha et al., 2013a;
                                                             Lavorato-Rocha et al., 2013b;
                                                             Rodrigues et al., 2013
  6/11/31\*/33\*/35\*       1 (1.7)          Anal canal      Soares et al., 2011
  Total                     59 (100.0)                       

Asterisks indicate high-risk HPV genotypes.

Discussion {#sec1-4}
==========

The causative role of HPV has been extensively studied in uterine cervical lesions; however, only a few such studies have been performed in prostate, anal canal, colorectal, penile, and vulvar tumors in Brazil and the world, clearly showing that more evidence is needed for the understanding of HPV in these cancers. It is known that cervical cancer remains an important health problem; however, relatively uncommon cancers of the anus, penis, and vulva have been shown to have increased incidence in recent years. It is believed that the changing occurrence of anogenital cancer may be mainly due to increased HPV transmission, due to changes in sexual behavior (Wakeham and Kavanagh, 2014).

The actual prevalence of HPV in non-cervical cancers remains controversial. While some studies have shown high prevalence (Urgoiti et al., 2014; Wakeham et al., 2017), others report that HPV is present in these cancers, but the prevalence is low; however, additional studies are needed for its confirmation (Bae, 2015; Yang et al., 2015). On the other hand, other studies claim that HPV has no influence on the development of cancer (Taherian et al., 2014). Our results reinforce the idea that HPV plays an important role in the development of cancer. The overall pooled prevalence in the studied cancers was high, being above 40%.

Infection by oncogenic HPV genotypes is a necessary cause for the development of cervical cancer (Walboomers et al., 1999), in contrast, HPV DNA detection was relatively less common in invasive cases of penile, prostate, vulvar, anal, and colorectal cancers (Backes et al., 2009; Damin et al., 2013; Urgoiti et al., 2014; Yow et al., 2014; Wakeham et al., 2017). The incidence of penile, vulvar and colorectal cancer is lower compared to cervical cancer (INCA, 2016), probably due to the lower susceptibility of tissues present in these organs to malignant transformation compared to the cervix (Palefsky, 2007). Already, studies available in the literature show that anal carcinoma rarely occurs in the absence of HPV, reinforcing the role of the virus as the main risk factor for this type of tumor (Abramowitz et al., 2011). Several concordant HPV genotypes, both oncogenic and non-oncogenic, can be found in anal specimens of women with coexisting HPV cervical infection, which may suggest similar susceptibility to the development of cancer in the anal canal, similar to that seen in the cervix (Guler et al., 2013).

Studies report that unlike cervical cancer, there may be several etiologies for non-cervical genital cancers, one being related to HPV and the other due to factors unrelated to HPV infection. Old age, country of birth, longstanding ulcerative colitis, red meat diet, obesity (Doubeni et al., 2012; Haggar et al., 2009), lifestyle, and genetic predisposition are related to colorectal cancer. Men who have sex with men, tobacco and immunosuppression are associated with anal cancer (Nelson and Benson, 2017). Immunosuppression, smoking, vulvar intraepithelial neoplasia, history of cervical cancer, and vulvar dystrophy are associated with vulvar cancer (Jones et al., 1997; Palefsky, 2009). Phimosis with chronic inflammation, lack of circumcision, inadequate hygiene practices, presence of other sexually transmitted diseases, number of sexual partners, and smoking (Calmon et al., 2011) are related to penile cancer. Regarding prostate cancer, little is known about the exact mechanisms involved in its development; however, environmental and hereditary components such as age, race, and family history play a crucial role in carcinogenesis (Shavers et al., 2009), it is believed that genital infections such as sexually transmitted infections, including HPV (Bae, 2015) are related to the etiology of prostatic inflammation which may possibly progress to prostate cancer (Puhr et al., 2016).

It is estimated that 40 to 50% of vulvar cancers have been associated with HPV (Bosch et al., 2013). Wakeham et al., (2017) found high-risk HPV genotype prevalence in 52% of vulvar cancer. In men, HPV DNA is found varying from 30 to 100% in penile cancers ("Human Papillomavirus and Related Diseases Report," 2017). Studies report a prevalence of approximately 48% (Backes et al., 2009; Miralles-Guri et al., 2009). A recent study published in Brazil (Afonso et al., 2017), described a 63.6% prevalence of HPV in penile cancer. HPV 16 was the most prevalent genotype (40.5%), followed by HPV 6 (16.5%) and HPV 45 (11.4%).

For prostate cancer, the prevalence varies from 0 to 41% (Singh et al., 2015; Yang et al., 2015; Yow et al., 2014). In both sexes, HPV DNA is detected in anal cancer (60.1 to 100%) (Aguiar et al., 2014) and colorectal cancer (14.1% to 60.8%) (Damin et al., 2013). For the meta-analysis, we investigated penile, vulvar and colorectal cancers, in which the prevalences were 42%, 43% and 67%, respectively. For prostate cancer, it was not possible to perform meta-analysis because the prevalence reported in the studies that we found corresponded to 0 and 3%. For anal canal cancer, meta-analysis was not performed because we found only one report during the period studied. In 2017, Guimarães et al. reported a prevalence of 81.5% of HPV in anal canal cancer in a study conducted in Brazil, with HPV 16 (100% of cases), followed by HPV 52 (31.8%).

Genotype 16 was the most frequent in all the studies that were part of this systematic review, corresponding to a prevalence of 54%, followed by genotypes 33, 6, 11, 18, 53, 35, 31 and 45. HPV 16 is the most common genotype of HPV reported in publications (Aguiar et al., 2014; Backes et al., 2009; Bae, 2015; Damin et al., 2013; De Vuyst et al., 2009; Hoots et al., 2009; "Human Papillomavirus and Related Diseases Report," 2017; Tewari et al., 2007; Yang et al., 2015;), followed by genotypes 18, 31, 33, and 45 (Bosch et al., 2013). Genotypes 6 and 11, of low risk, have also been presented as being of great importance for the development of neoplasias (Cornall et al., 2013).

It is believed that HPV, when associated with tissues, leads to the development of precursor lesions caused by viral infection. Researchers argue that the pathway is similar to HPV-mediated cervical carcinogenesis. Virus-induced carcinogenesis involves several steps: resistant infection caused by HPV is the initial causal event, with genetic alterations (Alves et al., 2001) and epigenetics (Afonso et al., 2017). The infected cell would present the malignant phenotype, due to the integration of the virus into the host-cell DNA and expression of the E6 and E7 oncoproteins, which antagonize the functions of the tumor-suppressor proteins p53 and pRb, respectively (Damin et al., 2013).

The mean age of the patients studied was approximately 63.2 years, and the great majority of the cases were verified to be above 60 years. The accumulation of exposure to different risk factors throughout life contributes to the higher prevalence of tumors at more advanced ages, especially coinfections with HPV (Bosch et al., 2013). Coinfection by two or more high- and low-risk HPV genotypes was found in all cancers studied. Coinfection was also identified in other studies and was related to the development of cancer (Afonso et al., 2017; Muñoz et al., 2003). Some genotypes of low risk, such as HPV 6, are well known for causing the majority of condylomas, and have been found to be important in several cancer cases, with a major presence of multiple coinfections with high-risk genotypes (Ferlay et al., 2013).

The distribution, type of HPV, and rate of infection may vary by geographical region (Giuliano et al., 2016), HPV detection method, study population and histological subtype of cancer ("Human Papillomavirus and Related Diseases Report," 2017). Different methods of detecting HPV show different sensitivities of detection of HPV DNA. Nevertheless, the results should be interpreted with caution, since DNA detection methods can easily suffer sample contamination which could probably bias the result (Abreu et al., 2012).

The high percentage of HPV infection in the studied cancers emphasizes the importance of control measures, with emphasis on HPV vaccination in an immunization program for both women and men. Two vaccines are available for the Brazilian population, the quadrivalent HPV vaccine, Gardasil^®^/Silgard^®^ (Sanofi Pasteur MSD/Merck Sharp and Dohme), which protects against infection from HPV 6, 11, 16, and 18, and the bivalent HPV vaccine, Cervarix^®^ (GlaxoSmithKline Biologicals), which protects against infection with HPV 16 and 18 (Lehtinen and Dillner, 2013). In 2015, the 9-valent HPV vaccine, Gardasil9 (Sanofi Pasteur MSD/Merck Sharp and Dohme), was licensed in Europe for the prevention of cancers and precancerous lesions of the cervix, vulva, vagina, and anus, as well as genital warts caused by HPV 6, 11, 16, 18, 31, 33, 45, 52, and 58 (European Medicines Agency). This vaccine protects against five high-risk HPV types not included in first-generation HPV vaccines (HPV 31, 33, 45, 52, and 58) (Joura et al., 2015). Although available vaccines have shown good results in reducing HPV infections and as a consequence of some types of cancer, there is still a need for public awareness.

Strengths and limitations of the study {#sec2-7}
--------------------------------------

This systematic review presents high robustness and considerable precision in the search for articles that present HPV prevalence in non-cervical genital cancers published in Brazil between 2006 and 2016. The MeSH terms and articles that were part of the search were decided by consensus among several professionals in this area, which increased the sensitivity of the work. In addition, meta-analyses were performed to determine the prevalence of HPV in cancer of three anatomical sites, as well as to determine the prevalence of HPV genotypes in these cancers. The main findings reported in the studies that have been done in this review were organized and detailed in numerous tables and figures, ensuring a good and realistic presentation of the data.

There are some inherent limitations to the research method: only two databases were surveyed, and although the total number of patients included in our meta-analysis is large, for many specific associations the number of studies that could actually be combined to provide absolute quantitative information or descriptive statistics was relatively small. This is a limitation that, unfortunately, cannot be overcome without access to primary data from all included publications. It is also assumed that the heterogeneity observed in the present review as well as in comparison with other studies conducted elsewhere in the world can be explained by regional differences in HPV prevalence, HPV type, distribution and/or non-risk factors related to HPV, as well as the various methods used for research, such as inclusion criteria, in the individual studies. Despite inherent limitations of the meta-analysis to some degree, our results are in agreement with the published literature, bringing a positive contribution regarding the development of cancer due to the presence of HPV.

Final considerations {#sec2-8}
--------------------

The systematic review and meta-analysis demonstrated high pooled HPV prevalence. High prevalence of HPV infection has also been found in penile cancer, in colorectal cancer, and in vulvar cancer. Although the highest prevalence of HPV 16 was confirmed in all cancers studied, significant prevalence of high- and low-risk genotypes 33, 6, 11, 18, 53, 35, 31 and 45 of HPV were also found. For the future, there is a need for prospective, multicenter, randomized studies to determine optimal treatment for patients based on HPV status, as well as the development of potential prevention programs, thus minimizing the possible development of tumors.
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